Furthermore, we found that the CDKN2A gene may predict GBM sensitivity and resistance to drugs.<h4>Discussion</h4>Our findings suggest that CRGs play a crucial role in GBM outcomes and provide new insights into CRG-related target drugs/molecules for cancer prevention and treatment. Here, CDKN2A is linked to glioblastoma.